ECSP088992A - Inhibidores de akt (proteina cinasa b) - Google Patents

Inhibidores de akt (proteina cinasa b)

Info

Publication number
ECSP088992A
ECSP088992A EC2008008992A ECSP088992A ECSP088992A EC SP088992 A ECSP088992 A EC SP088992A EC 2008008992 A EC2008008992 A EC 2008008992A EC SP088992 A ECSP088992 A EC SP088992A EC SP088992 A ECSP088992 A EC SP088992A
Authority
EC
Ecuador
Prior art keywords
cinase
protein
akt inhibitors
compounds
salt
Prior art date
Application number
EC2008008992A
Other languages
English (en)
Inventor
Michael Ray Myers
Christopher Randall Schmid
Renhua Li
Sajan Joseph
Aktham Aburub
Jenny Pinggi Dai
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP088992A publication Critical patent/ECSP088992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol o una sal del mismo farmacéuticamente aceptable o un hidrato del compuesto o la sal del mismo, como inhibidores de AKt, que son agentes antineoplásicos y/o antivirales, así como también a composiciones que comprende estos compuestos y a métodos para usar estos compuestos
EC2008008992A 2006-06-20 2008-12-18 Inhibidores de akt (proteina cinasa b) ECSP088992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80526006P 2006-06-20 2006-06-20
US88576507P 2007-01-19 2007-01-19

Publications (1)

Publication Number Publication Date
ECSP088992A true ECSP088992A (es) 2009-01-30

Family

ID=38834248

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008992A ECSP088992A (es) 2006-06-20 2008-12-18 Inhibidores de akt (proteina cinasa b)

Country Status (28)

Country Link
US (1) US7998977B2 (es)
EP (1) EP2035385B1 (es)
JP (1) JP2009541335A (es)
KR (1) KR101067551B1 (es)
AR (1) AR061240A1 (es)
AT (1) ATE455102T1 (es)
AU (1) AU2007261120A1 (es)
BR (1) BRPI0713136A2 (es)
CA (1) CA2652612A1 (es)
CL (1) CL2007001752A1 (es)
DE (1) DE602007004333D1 (es)
DK (1) DK2035385T3 (es)
DO (1) DOP2008000053A (es)
EA (1) EA015712B1 (es)
EC (1) ECSP088992A (es)
ES (1) ES2336630T3 (es)
HR (1) HRP20100147T1 (es)
IL (1) IL195005A0 (es)
MA (1) MA30757B1 (es)
MX (1) MX2008015904A (es)
NO (1) NO20090289L (es)
PE (1) PE20080338A1 (es)
PL (1) PL2035385T3 (es)
PT (1) PT2035385E (es)
SI (1) SI2035385T1 (es)
TN (1) TNSN08529A1 (es)
TW (1) TW200812970A (es)
WO (1) WO2007149730A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EA027343B1 (ru) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US10123997B2 (en) * 2015-06-15 2018-11-13 Yong Liao Target for treating hepatitis B virus
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CA3186565A1 (en) * 2020-07-22 2022-01-27 Lei Miao Unit dosage composition of akt inhibitor
US20230271958A1 (en) * 2020-07-22 2023-08-31 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
CN1768040A (zh) * 2003-03-28 2006-05-03 伊莱利利公司 作为akt(蛋白激酶b)抑制剂的异喹啉－5－磺酸酰胺
GB0317315D0 (en) 2003-07-24 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)

Also Published As

Publication number Publication date
TW200812970A (en) 2008-03-16
US20090221633A1 (en) 2009-09-03
JP2009541335A (ja) 2009-11-26
MX2008015904A (es) 2009-01-12
EP2035385A2 (en) 2009-03-18
HRP20100147T1 (hr) 2010-04-30
MA30757B1 (fr) 2009-10-01
SI2035385T1 (sl) 2010-05-31
US7998977B2 (en) 2011-08-16
CL2007001752A1 (es) 2008-01-18
NO20090289L (no) 2009-01-19
KR20090015978A (ko) 2009-02-12
WO2007149730A3 (en) 2008-04-24
DOP2008000053A (es) 2009-01-15
BRPI0713136A2 (pt) 2012-04-17
AR061240A1 (es) 2008-08-13
PL2035385T3 (pl) 2010-06-30
KR101067551B1 (ko) 2011-09-27
ATE455102T1 (de) 2010-01-15
PE20080338A1 (es) 2008-04-25
PT2035385E (pt) 2010-03-01
ES2336630T3 (es) 2010-04-14
DK2035385T3 (da) 2010-03-22
EP2035385B1 (en) 2010-01-13
TNSN08529A1 (en) 2010-04-14
CA2652612A1 (en) 2007-12-27
AU2007261120A1 (en) 2007-12-27
DE602007004333D1 (de) 2010-03-04
EA015712B1 (ru) 2011-10-31
IL195005A0 (en) 2009-08-03
WO2007149730A2 (en) 2007-12-27
EA200970041A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
EA200970856A1 (ru) Ингибиторы пути хеджхога
GT201100181A (es) "inhibidores de proteina cinasa"
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
UA94129C2 (ru) Соединения для ингибирования митоза
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
CR20110339A (es) Compuestos útiles para inhibir chk1
CY1118012T1 (el) Συνθεσεις αναστολεων κινασης και η χρηση αυτων για την αγωγη καρκινου και αλλων νοσηματων σχετικων προς τις κινασες
UY32730A (es) Inhibidores de cyp17
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
ECSP055867A (es) Derivados de pirrolopirimidina
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NI201000119A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis.
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
SV2011003902A (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5- hidroxitriptamina-6
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
GT200600117A (es) Nuevos compuestos farmaceuticos
CR10199A (es) Derivados de benzimidazol
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
NI201100035A (es) Agentes antifúngicos.
DK2099461T3 (da) LNA Nukleoside Phosphoramidates
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение